Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Income from Continuing Operations (2016 - 2025)

Perspective Therapeutics' Income from Continuing Operations history spans 16 years, with the latest figure at 25969000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 71.73% year-over-year to 25969000.0; the TTM value through Sep 2025 reached 107973000.0, down 689.45%, while the annual FY2024 figure was 79989000.0, 3117.31% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 25969000.0 at Perspective Therapeutics, down from 21999000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 24484000.0 in Q4 2023 and bottomed at 41828000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 4068000.0 (2022), against an average of 8151368.42.
  • The largest annual shift saw Income from Continuing Operations surged 1375.21% in 2023 before it tumbled 1179.91% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 330000.0 in 2021, then crashed by 681.82% to 1920000.0 in 2022, then soared by 1375.21% to 24484000.0 in 2023, then tumbled by 270.84% to 41828000.0 in 2024, then skyrocketed by 37.91% to 25969000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Income from Continuing Operations are 25969000.0 (Q3 2025), 21999000.0 (Q2 2025), and 18177000.0 (Q1 2025).